
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL Inc has demonstrated significant stock appreciation of nearly 90% in the last month, reflecting growing investor confidence stemming from favorable PATHFINDER 2 ESMO data and a bullish outlook on the NHS Galleri trial. The company's comprehensive Total Addressable Market (TAM) analysis reveals substantial revenue opportunities, estimated at approximately $3.7 billion in the UK by 2026, with potential growth to $4.0 billion by 2035. Additionally, GRAIL's strategic partnerships aim to enhance access to these markets, positioning the company favorably within the multi-cancer early detection sector despite lingering uncertainties around regulatory approvals and Medicare reimbursement.
Bears say
GRAIL Inc has consistently reported significant net losses since its inception and anticipates ongoing losses due to the costs associated with studies, regulatory approvals, and infrastructure expansion. The company faces multiple challenges, including potential delays in Congressional action for CMS reimbursement, adoption difficulties for its innovative multi-cancer early detection test, and competitive pressures from larger diagnostics firms with established infrastructures. Additionally, uncertainties regarding financing and regulatory timelines, coupled with high selling, general, and administrative expenses, may hinder GRAIL's ability to effectively commercialize its products and achieve financial stability.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares